DOCSLIB.ORG

Low-Dose Baclofen for Treatment of Alcohol Dependence

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Low-Dose Baclofen for Treatment of Alcohol Dependence Case notes I Alcohol dependence Low-dose baclofen for treatment of alcohol dependence Mohamed Al-Garhy MD, Sona Varghese MD Alcohol use disorder (AUD) is a and reduced heavy drinking with muscle relaxants may have dissuaded growing problem in the Arabian topiramate but with side-effects, providers from using baclofen for Gulf region. Although drug including weight loss, dizzi ness and AUD, but it is a reasonable alternative treatment for AUD has largely neurocognitive problems, often lead- when FDA-approved treatments fail. 4 remained the same in previous ing to discontinuation. Baclofen is primarily eliminated by Molecules such as nalmefene the kidneys, so it can be used in liver years, the dosage of the and baclofen could broaden the impairment.10 Baseline renal tests medication has always been a treatment objectives, especially should be performed before admin- subject of interest. This report reduction of alcohol consumption, istering baclofen, and a negative highlights the case of a patient an objective that is more readily pregnancy test obtained for women on low-dose baclofen and the accepted by some patients.5 of childbearing age. sustained improvement he Baclofen is a GABAb receptor achieved with the treatment. agonist that is FDA approved for Presentation treating spasticity. Because GABA A 29-year-old male patient started lcohol dependence is managed transmission is down-regulated in using alcohol six years ago almost Athrough a combination of treat- chronic alcohol use disorder (AUD), daily. He developed tolerance grad- ment including pharmacotherapy it is a commonly targeted neuro- ually to reach a daily intake of more and psychosocial approaches. transmitter when developing medi- than 25 units. He developed uncom- Although psychosocial treatments cations for AUD.6 plicated alcohol withdrawal on are effective in reducing alcohol con- GABAa receptors are fast-acting attempting to reduce the amount or sumption and in maintaining absti- inhibitory ion channels, and its ago- to abstain. Prior to this he had no nence in many patients, 40% to 70% nists (eg benzodiazepines) have a history of substance misuse or psy- of patients resume drinking within a significant abuse and cross- addiction chiatric disorders. He had never year after treatment.1 liability. GABAb receptors, however, been treated before in rehabilitation Over the last decade, a variety of are slow-acting through a complex centre and had no legal problems medications have been proposed as cascade of intracellular signals, and related to his alcohol use and no putative therapeutic agents for alco- therefore GABAb agonists such as family history of substance misuse or hol dependence based upon their baclofen have been studied for treat- psychiatric disorders. ability to modulate corticomesolim- ing addiction.7 Four years ago, he was brought by bic dopamine function.2 A double-blind, randomised, pla- his father to the emergency room of The Food and Drug Administra- cebo-controlled trial of baclofen Sheikh Khalifa Medical City (a gen- tion (FDA) in the USA has approved showed that a significantly higher eral hospital in Abu Dhabi, United three medications for the treatment number of patients who achieved Arab Emirates), having not gone to of alcohol dependence – disulfiram, and maintained abstinence through- work for two months and being intox- naltrexone and acamprosate. out the experimental period were icated most of the day. He was admit- Although naltrexone is relatively found in the group of patients treated ted for the first time to a drug and well tolerated, the potential risk with fixed-dose baclofen compared alcohol inpatient treatment unit fol- of hepatotoxicity at high dose with subjects treated with placebo.8 lowing 24-hour observation in the requires caution when treating In studies for AUD, the side-effect medical ward for development of patients with liver disease. Moreover, profile for baclofen was relatively withdrawal symptoms from chronic as it is an opiate antagonist, it is con- benign. Nausea, fatigue, sleepiness, alcohol use. Prior to admission, he traindicated in alcoholics who also vertigo, and abdominal pain were was investigated for any medical use opiate.3 reported; overall, baclofen was found conditions. His liver enzymes and Short-term randomised trials have to be safe and to have no abuse liabil- gamma-glutamyl transpeptidase shown improved rates of abstinence ity.9 The addictive potential of other (GGT) were slightly elevated, but he 6 I Progress in Neurology and Psychiatry I Vol. 21 Iss. 3 2017 www.progressnp.com Alcohol dependence I Case notes had no medical issues that would war- discharged after four weeks and since Declaration of interests rant immediate medical attention. then has remained sober and attends No conflicts of interest were declared. While on the ward, he denied regular follow-­­up visits in the outpa- symptoms suggestive of psychiatric tient clinic. His medication (baclofen Dr Al-Garhy is a Consultant disorders or other substance misuse. 20mg three times a day) is provided Psychiatrist and Dr Varghese is a He was diagnosed according to on a monthly basis. Liver enzymes Specialist Psychiatrist, both at the DSM-IV criteria as suffering from and GGT have returned to normal. Chemical Dependency Unit, Sheikh alcohol dependence. He was com- Psychosocial support is regularly pro- Khalifa Medical City, Abu Dhabi, menced on chlordiazepoxide 20mg vided to prevent relapse with a focus United Arab Emirates. three times a day and thiamine on self-esteem and assertiveness 100mg daily. He completed the issues. His family supports him and References detoxification process safely and was he resumed work shortly after dis- 1. Swift RM. Drug therapy for alcohol dependence. N Engl J Med 1999;340:1482–90. discharged after one month. The charge from the inpatient unit. 2. Ma JZ, Ait-Daoud N, Johnson BA. Topiramate patient failed to attend the outpa- reduces the harm of excessive drinking: tient clinic following discharge. Discussion implications for public health and primary care. Addiction 2006;101:1561–8. A year later, he had two subse- A case of alcohol dependence with 3. Krishnan-Sarin S, O’Malley S, Krystal JH. quent readmissions, for four and multiple relapses has been Treatment implications: using neuroscience three weeks. He completed detoxifi- described: the patient’s condition to guide the development of new pharma- cotherapies for alcoholism. Alcohol Res Health cation in both admissions, but again had been deteriorating until he was 2008;31(4):400–7. failed to adhere to follow-ups after commenced on baclofen. In our 4. Friedmann PD. Clinical practice. Alcohol use in adults. Engl J Med 2013;368:365–73. discharge. His relapses usually hap- experience, baclofen was shown to 5. Paille F, Martini H. Nalmefene: a new pened shortly after discharge mostly be effective even in small doses – as approach to the treatment of alcohol due to work stressors and poor moti- effective as other FDA-approved dependence. Subst Abuse Rehabil 2014;5: 87–94. vation to recover. In all the three medications – for alcohol use disor- 6. Garbutt JC, Kampov-Polevoy AB, Gallop R, et admissions after completion of ders. Baclofen in small doses could al. Efficacy and safety of baclofen for alcohol detoxification, he attended an inpa- help many patients to achieve com- dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res tient rehabilitation program for plete abstinence, which is the pri- 2010;34:1849–57. relapse prevention. mary goal in treating alcohol use 7. Robinson S, Meeks TW, Geniza Z. Medication for alcohol use disorder: Which agents work His last admission was three years disorders. There is a growing need best? Current Psychiatry 2014;13(1):22–9. ago, where he came voluntarily for for future research to reassess the 8. Addolorato G, Caputo F, Capristo E, et al. rehabilitation. Following detoxifica- current guidelines used in the treat- Baclofen efficacy in reducing alcohol craving and tion, he was started on baclofen 5mg ment of AUD. It is always important intake: a preliminary double-blind ran domized controlled study. Alcohol Alcohol 2002:37;504–8. three times a day and over a two-week to discuss all options available with 9.Johnson BA. Update on neuropharma- period, baclofen was increased grad- the patient and their families before cological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol ually to reach 20mg three times a day. initiating treatment. 2008;75(1):34–56. At that dose, the patient acknowl- 10. Addolorato G, Leggio L, et al. Dose-response edged that baclofen greatly reduced Acknowledgements effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a his craving and he expressed total We are grateful to the patient and his randomized, double-blind, placebo-controlled indifference toward alcohol. He was family for their time and support. trial. Alcohol Alcohol 2011;46(3):312–7. www.progressnp.com Progress in Neurology and Psychiatry I Vol. 21 Iss. 3 2017 I 7.
Load more

Recommended publications
  • Baclofen Overdose D
    Postgraduate Medical Journal (February 1980) 56, 108-109 Postgrad Med J: first published as 10.1136/pgmj.56.652.108 on 1 February 1980. Downloaded from Baclofen overdose D. J. LIPSCOMB* T. J. MEREDITHt M.B.. M.R.C.P. M.A., M.R.C.P. *Department of Medicine, Peterborough District Hospital, Peterborough PE3 6DA, and tPoisons Unit, Guy's Hospital, London SE] 9RT Summary Case report A 57-year-old woman suffering from multiple sclerosis A 51-year-old woman, who had suffered from took an estimated 1500 mg of baclofen. She became multiple sclerosis for 15 years, was prescribed baclo- deeply unconscious with generalized flaccid muscle fen 40 mg daily as part of her treatment for spastic paralysis and absent tendon reflexes. Toxicological paraplegia. One morning, she was found lying in analysis confirmed the presence of baclofen together bed unconscious and was admitted to hospital. with small amounts of paracetamol and glutethimide. Information given by her husband suggested that an Supportive therapy, including assisted ventilation for overdose of baclofen (consisting of 152 10-mg 3 days, led to complete recovery; anticonvulsant tablets) had been taken about 2 5 hr before being drugs were necessary for the treatment of grand mal found unconscious. On arrival in hospital 90 min fits. The clinical features and treatment of baclofen later, she was deeply unconscious and unresponsive overdose are discussed. to painful stimuli. Respiration was depressed and the cough reflex was absent. She was intubated without Introduction resistance and ventilated; gastric lavage was per-Protected by copyright. Baclofen (Lioresal, Ciba) is widely used in the formed but no tablets were returned in the lavage treatment of muscle spasticity.
    [Show full text]
  • The Use of Intravenous Baclofen As Therapy for the Γ-Hydroxybutyric Acid Withdrawal Syndrome
    Research Article Remedy Open Access Published: 12 Jun, 2017 The Use of Intravenous Baclofen as Therapy for the γ-hydroxybutyric Acid Withdrawal Syndrome Marc Sabbe1*, Francis Desmet1 and Sabrina Dewinter2 1Department of Emergency Medicine, University Hospitals, Catholic University of Leuven, Belgium 2Department of Pharmacy, University Hospitals, Catholic University of Leuven, Belgium Abstract Introduction: In this case series with three patients, we introduced baclofen, a γ-aminobutyric acid type B(GABA-B) receptor agonist, for treatment of the γ-hydroxybutyric acid (GHB) withdrawal syndrome. Materials and Methods: Single center case series performed on three patientswith a GHB withdrawal syndrome. They initially received massive doses of benzodiazepines, without sufficient effect. Two patients also received an unsuccessful continuous dexmedetomidine drip. In all patients, intravenous baclofen was started, with an intravenous loading dose between 0.5 and 2 milligrams (mg) to achieve a therapeutic level. Thereafter a continuous intravenous dose between 0.5 and 1 mg per hour for 12 h was administered to maintain a steady state. After that, baclofen was substituted orally with a daily oral dose varying between 20 mg and 40 mg which could be downgraded and stopped over the next days. They all continued to receive a standard benzodiazepine regimen during the baclofen trial. Results and Discussion: Main outcome measurements were the degree of withdrawal symptoms and the need for benzodiazepines during baclofen treatment. In all patients, a significant reduction of the GHB withdrawal syndrome was noted. A standard daily regimen of baseline benzodiazepine dosing between 40 mg and 80 mg diazepam was sufficient. Adverse effects of baclofen use were absent.
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: wolfgang.froestl@acimmune.com GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • Baclofen and Other GABAB Receptor Agents Are Allosteric Modulators of the CXCL12 Chemokine Receptor CXCR4
    The Journal of Neuroscience, July 10, 2013 • 33(28):11643–11654 • 11643 Cellular/Molecular Baclofen and Other GABAB Receptor Agents Are Allosteric Modulators of the CXCL12 Chemokine Receptor CXCR4 Alice Guyon,1,2,3 Amanda Kussrow,4 Ian Roys Olmsted,4 Guillaume Sandoz,1,2,5 Darryl J. Bornhop,4* and Jean-Louis Nahon1,2,6* 1Universite´ de Nice Sophia Antipolis, 06103 Nice, France, 2Centre National de la Recherche Scientifique (CNRS), Institut de Pharmacologie Mole´culaire et Cellulaire, UMR 7275, 06560 Valbonne, France, 3Department of Molecular and Cellular Biology and Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, California 94720, 4Vanderbilt Institute of Chemical Biology, Nashville, Tennessee 37235-1822, 5Institute of Biology Valrose, CNRS UMR 7277, INSERM UMR 1091, Laboratories of Excellence, Ion Channel Science and Therapeutics, 06103 Nice, France, 6Station de Primatologie—UPS 846—Centre CNRS, RD56, 13790 Rousset sur Arc, France CXCR4, a receptor for the chemokine CXCL12 (stromal-cell derived factor-1␣), is a G-protein-coupled receptor (GPCR), expressed in the immune and CNS and integrally involved in various neurological disorders. The GABAB receptor is also a GPCR that mediates metabotropic action of the inhibitory neurotransmitter GABA and is located on neurons and immune cells as well. Using diverse approaches, we report novel interaction between GABAB receptor agents and CXCR4 and demonstrate allosteric binding of these agents to CXCR4. First, both GABAB antagonistsandagonistsblockCXCL12-elicitedchemotaxisinhumanbreastcancercells.Second,aGABAB antagonistblocksthepotentiationby CXCL12ofhigh-thresholdCa 2ϩ channelsinratneurons.Third,electrophysiologyinXenopusoocytesandhumanembryonickidneycellline293 ϩ cells in which we coexpressed rat CXCR4 and the G-protein inward rectifier K (GIRK) channel showed that GABAB antagonist and agonist modified CXCL12-evoked activation of GIRK channels.
    [Show full text]
  • Gastroparesis: 2014
    GASTROINTESTINAL MOTILITY AND FUNCTIONAL BOWEL DISORDERS, SERIES #1 Richard W. McCallum, MD, FACP, FRACP (Aust), FACG Status of Pharmacologic Management of Gastroparesis: 2014 Richard W. McCallum Joseph Sunny, Jr. Gastroparesis is characterized by delayed gastric emptying without mechanical obstruction of the gastric outlet or small intestine. The main etiologies are diabetes, idiopathic and post- gastric and esophageal surgical settings. The management of gastroparesis is challenging due to a limited number of medications and patients often have symptoms, which are refractory to available medications. This article reviews current treatment options for gastroparesis including adverse events and limitations as well as future directions in pharmacologic research. INTRODUCTION astroparesis is a syndrome characterized by documented gastroparesis are increasing.2 Physicians delayed emptying of gastric contents without have both medical and surgical approaches for these Gmechanical obstruction of the stomach, pylorus or patients (See Figure 1). Medical therapy includes both small bowel. Patients can present with nausea, vomiting, prokinetics and antiemetics (See Table 1 and Table 2). postprandial fullness, early satiety, pressure, fullness The gastroparesis population will grow as diabetes and abdominal distension. In addition, abdominal pain increases and new therapies will be required. What located in the epigastrium, and distinguished from the do we know about the size of the gastroparetic term discomfort, is increasingly being recognized population? According to a study from the Mayo Clinic as an important symptom. The main etiologies of group surveying Olmsted County in Minnesota, the gastroparesis are diabetes, idiopathic, and post gastric risk of gastroparesis in Type 1 diabetes mellitus was and esophageal surgeries.1 Hospitalizations from significantly greater than for Type 2.
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Drug Effects on EEG
    REVIEW ARTICLES Drug Effects on EEG Warren T. Blume Abstract: Although excess beta activity and a mild theta increase may SPECIFIC MODIFICATIONS be the most common EEG alterations associated with medication, more Beta remarkable changes may also appear. Although changes such as diffuse An augmentation of voltage, field distribution, and persis- delta, triphasic waves, bisynchronous spikes or polyspikes, burst sup- tence of normally appearing 15 to 25 Hz Beta activity most pression or electrocerebral inactivity may indicate a dismal prognosis commonly indicates the presence of a medication effect on the under many circumstances; these patterns may fully resolve to a normal EEG (Figs. 1–3). Barbiturates and benzodiazepines most prom- EEG if drug administration is the unique or principal cause. inently produce this effect ( G. Bauer and R. Bauer, 2005; Van Cott and Brenner, 2003). Greater than usual theta activity may Key Words: Drug effects, EEG, Prognosis. accompany such beta excess (Blume et al., 2002). Central (J Clin Neurophysiol 2006;23: 306–311) nervous system stimulants such as cocaine, amphetamines, and methylphenidate as well as tricyclic antidepressants may evoke greater beta activity at low voltage (G. Bauer and R. Bauer, s a substantial proportion of patients undergoing electro- 2005; Van Cott and Brenner, 2003). Withdrawal from alcohol Aencephalography (EEG) take one or more medications of and barbiturates may produce a similar low voltage EEG with various kinds, the electroencephalographer must bear their beta activity. effects in mind when reading the EEG and phrasing its clinical Beta activity is more abundantly expressed by medication interpretation. Moreover, an asymmetry of drug effects may in children than in adults and with acute rather than chronic reflect a focal or hemispheric lesion whose EEG effects may not administration.
    [Show full text]
  • AUD-Patient AD-Baclofen-HCV
    What are some side effects How long do I have to take of baclofen? baclofen? Common What Can I Do if I You and your provider will decide on Side Effects Experience This? your treatment plan. Drowsiness Most common side Most take baclofen for at least effect. Your body will 6 months and often longer. likely adjust over time Headache You may take a non- opioid pain reliever For more information about drinking if recommended by and Hepatitis C visit the VA’s website: your provider Nausea • Take with food http://www.hepatitis.va.gov/ or Upset • Eat plain rice, toast, patient/daily/alcohol/index.asp Stomach or crackers Dizziness Rise slowly to prevent falls Veteran's Crisis Line 1-800-273-TALK (8255) or Do not drive, use machinery, or do Text - 838255 anything that may be dangerous until you know how the medicine affects you. U.S. Department of Veterans Affairs Notify your provider if you experience: Veterans Health Administration VA PBM Academic Detailing Service ¡ Allergic reactions (skin rash, hives, swelling of lips) Baclofen ¡ Chest pain Contact info: ¡ Hallucinations Using Medications to ¡ Seizures Help Manage Alcohol Use All medicines can have side effects. Disorder with Hepatitis C Not everyone has side effects though. They usually get better as your body gets used to the new medicine. Talk with your provider or pharmacist if May 2017 PBM Academic Detailing Service any of the above side effects trouble you. IB 10-949, P96831 www.va.gov How can baclofen help me What do I need to know before Drinking and Hepatitis C cut down or stop drinking? starting baclofen? If you have Hepatitis C, drinking Baclofen is a medication that reduces alcohol can be the single biggest your urge or craving to drink, and can threat to your health.
    [Show full text]
  • Information for the Patient Nicardipine 10 Mg/10 Ml Solution for Injection Nicardipine Hydrochloride
    Package leaflet: Information for the patient Nicardipine 10 mg/10 ml solution for injection Nicardipine hydrochloride Read all of this leaflet carefully before you are given this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or nurse. • If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. The name of your medicine is “Nicardipine 10 mg/10 ml solution for injection” but in the rest of the leaflet it will be called as ‘Nicardipine solution for injection’. What is in this leaflet 1. What Nicardipine solution for injection is and what it is used for 2. What you need to know before you are given Nicardipine solution for injection 3. How to take Nicardipine solution for injection 4. Possible side effects 5. How to store Nicardipine solution for injection 6. Contents of the pack and other information 1. What Nicardipine solution for injection is and what it is used for Nicardipine solution for injection contains the active substance Nicardipine hydrochloride, which belongs to a group of medicines called calcium channel blockers. Nicardipine solution for injection is used to treat very severe high blood pressure. It can also be used to control high blood pressure after an operation. You must talk to a doctor if you do not feel better or if you feel worse. 2. What you need to know before you are given Nicardipine solution for injection Do not take Nicardipine solution for injection: • If you are allergic to Nicardipine or any of the other ingredients of this medicine (listed in section 6) • If you have chest pain • If your high blood pressure is because of narrowing of a heart valve or other defects in the heart • If you have had a heart attack in the last eight days • If you have been told by your doctor that you have an intolerance to some sugars.
    [Show full text]
  • Complications of Baclofen Overdosage K
    Postgrad Med J: first published as 10.1136/pgmj.56.662.865 on 1 December 1980. Downloaded from Postgraduate Medical Journal (December 1980) 56, 865-867 Complications of baclofen overdosage K. GHOSE K. M. HOLMES Ph.D., M.R.C.P. M.R.C.P. K. MATTHEWSON M.B. B.S. The Cumberland Infirmary, Carlisle, Cumbria CA2 7HY Summary 45 baclofen tablets (450 mg) which had been taken A 39-year-old female patient who had been receiving about 8-10 hr previously. She had been prescribed 30 mg of baclofen daily for 5 months was admitted to this medication for muscle spasticity associated with the hospital about 12 hr after an overdose of this basilar impression due to an arachnoid cyst of the drug (450 mg). On admission, she was comatose, posterior fossa about 5 months before this incident. flaccid, and in respiratory failure. Later she developed On admission, she was comatose, hypotonic, and muscle twitchings and had several epileptic fits. She all reflexes were absent. Pupils were dilated and Protected by copyright. was treated symptomatically and became conscious fixed but there was no evidence of papilloedema or within 36 hr. However, approximately 65 hr after the pulmonary oedema. Her BP was 110/70mmHg overdose she developed sinus tachycardia which was and a routine ECG was normal with a heart rate of successfully treated with oral propranolol. Plasma 80/min. However, she had central cyanosis and her concentrations, as measured on days 2 and 3, were respiration was slow, irregular and shallow. She within the therapeutic range but the elimination was ventilated and treated with various supportive half-life was prolonged.
    [Show full text]
  • Arbaclofen Placarbil, a Novel R-Baclofen Prodrug: Improved ADME
    JPET Fast Forward. Published on June 5, 2009 as DOI: 10.1124/jpet.108.149773 JPETThis Fast article Forward. has not been Published copyedited and on formatted. June 5, The 2009 final asversion DOI:10.1124/jpet.108.149773 may differ from this version. JPET#149773 Arbaclofen Placarbil, A Novel R-Baclofen Prodrug: Improved ADME Properties Compared to R-Baclofen. Ritu Lal, Juthamas Sukbuntherng, Ezra H.L. Tai, Shubhra Upadhyay, Fenmei Yao, Mark S. Warren, Wendy Luo, Lin Bu, Son Nguyen, Jeanelle Zamora, Ge Peng, Tracy Dias, Ying Bao, Maria Ludwikow, Thu Phan, Randall A. Scheuerman, Hui Yan, Mark Gao, Downloaded from Quincey Q. Wu, Thamil Annamalai, Stephen P. Raillard, Kerry Koller, Mark A. Gallop, and Kenneth C. Cundy jpet.aspetjournals.org XenoPort, Inc., Santa Clara, CA, U.S.A. at ASPET Journals on September 26, 2021 1 Copyright 2009 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on June 5, 2009 as DOI: 10.1124/jpet.108.149773 This article has not been copyedited and formatted. The final version may differ from this version. JPET#149773 Running Title: Arbaclofen Placarbil: ADME and Pharmacokinetics Corresponding Author: Ritu Lal, Ph.D. XenoPort, Inc. 3410 Central Expressway Santa Clara, CA 95051 Phone: 408-616-7199 FAX: 408-616-7212 Downloaded from E-mail: ritu.lal@xenoport.com jpet.aspetjournals.org Number of text pages: 40 Number of Tables: 8 Number of Figures: 5 at ASPET Journals on September 26, 2021 Number of References: 22 Number of words in Abstract: 214 Number of words in Introduction: 478 Number of words in Discussion: 1494 List of Abbreviations: AUC, area under the blood concentration versus time curve; AUC(0-inf), area under the blood concentration versus time curve extrapolated to infinity; C0, concentration in blood extrapolated to time zero following intravenous administration; Cmax, maximum concentration in blood; Caco-2, human colonic adenocarcinoma cell line; CSF, cerebrospinal fluid; GABAB, gamma-aminobutyric acid-B; GERD, gastroesophageal 2 JPET Fast Forward.
    [Show full text]
  • Compounding for Vulvar Conditions
    Multidisciplinary Evaluation and Treatment of Vulvar Disorders The Role of Compounding Pharmacy Tara Thompson PharmD., RPh. Innovation Compounding Pharmacy Disclosures • Innovation Compounding Pharmacy – Kennesaw, GA Objectives • To understand the purpose of a compounding pharmacy • To familiarize the benefits & drawbacks of compounding • To delineate compounding options for the vulvar region • To determine appropriate formulations for commonly prescribed vulvar preparations What is Compounding? • Compounding pharmacists work directly with prescribers including physicians, NP/PAs, physical/sex therapists, and other clinicians to create customized medication solutions for patients whose healthcare needs cannot be met by manufactured medications. • 5000 year old profession, the oldest form of pharmacy • Regulated by State Boards of Pharmacy and Accreditation Boards • “Thinking outside of the box” • Manipulating the dosage form! • Customized, individualized medicine tailored to the patient’s specific need How Do I Choose a Compounding Pharmacy? • Licensed in your State • Pharmacist Knowledge and Access • Adherence to USP Guidelines, Testing • USP <795> - Non-Sterile Compounding • USP <797> - Sterile Compounding • Diversity of Portfolio to your Practice Needs • Pelvic Health/FSD/IC • Pricing and Patient Care/Access • Reputation • Compounding Ability and Dosage Form Assortment • Most Important – Accreditation and Inspection!! PCAB – Pharmacy Compounding Accreditation Board • A service of the Accreditation Commission for Healthcare (ACHC) •
    [Show full text]